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Abstract 
 The goal of this project was to clone and express the antimicrobial peptide protegrin 1 
(PG-1).  Initially a yeast system was chosen but was discarded due to technical difficulties.  
Invitrogen’s bacterial T7 expression system was chosen next to express the peptide.  PG-1 
expression was verified by anti-his immunoblot and then the peptide was purified by IMAC.  Its 
activity was verified using a Bacillus subtillis radial diffusion assay. 
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1 Introduction 
 
Bacterial infections have been a problem for macroorganisms for as long as they have 
existed on the earth.  Humans are not an exception to this concern.  As science has progressed 
many means to combat bacteria have been developed.  One of these means is antibiotics.  These 
compounds are able to attack bacteria on the molecular level and defeat them directly.  Many 
higher organisms, however, have built-in antibiotics known as antimicrobial peptides.  These 
proteins act as endogenous antibiotics and protect the host animal from a wide range of bacterial 
pathogens (Cho et al 1998). 
 This masters thesis focused on the development of an artificial gene for an antimicrobial 
peptide and subsequent expression of the gene in host cells.  Antimicrobial peptides can be found 
in most animals, and in the vast majority of cases an animal has several different kinds of 
antimicrobial peptides.  Alpha defensins, human antimicrobial peptides, function in neutrophils 
where they aid the cell in killing bacteria and fungi once the neutrophil has ingested the 
pathogens (Lehrer and Ganz, 1999).  Human beta defensins have also been shown to act as 
chemo attractants for memory T-cells in addition to damaging microbial membranes (Yang et al 
1999).  Another very broad class of antimicrobial peptides, the cathelicidins, are also found in 
the neutrophils of various animals.  These antimicrobial peptides are synthesized at the C- 
terminal end of a highly conserved cathelin domain.  The cathelin domain serves to keep the 
antimicrobial peptide in an inactive storage form.  This domain is widespread among mammals, 
which suggests it has considerable value.  Once the cathelin bound peptide has been synthesized, 
it is processed by neutrophil elastase and the peptide is released from the cathelin domain.  This 
cleavage converts it to its active form (Shi and Ganz 1998).  One cathelicidin, LL-37, has been 
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 localized to epithelial cells of the human airway, and to serous and mucous cells of the 
submucousal glands.  LL-37 has shown activity against Pseudomonas aeruginosa, a bacterium 
that causes chronic lung infections (Turner et al. 1998). 
 Another class of antimicrobial peptide is the protegrins, which are the focus of this thesis.  
These peptides were originally found in porcine leukocytes, and are 16 – 18 amino acid residues 
in length.  They are a member of the cathelicidin family.  Protegrins show broad-spectrum 
activity and have been proven active against Candida albicans, Listeria monocytogenes, 
Staphylococcus epidermidis, and Bacillus subtilis along with several other strains of bacteria 
(Yasin et al. 1996; Qu et al. 1997; Steinberg et al. 1997; Cho et al. 1998; Shi and Ganz 1998; 
Turner et al. 1998).    
 Antimicrobial peptides in general are being widely studied right now in order to 
determine their potential utility in medicine.  The ability to produce synthetic analogues for use 
in treatment of bacterial infections is also being investigated.  If antimicrobial peptides can be 
created using a cloned gene then it would be possible to produce them in sufficient quantities at a 
reasonable cost.  The high cost of a fair number of drugs is due to the fact that they must be 
isolated directly from their natural environment.  In some cases this can prove to be very 
difficult.  Studies have already been done examining the effectiveness of murine analogues of 
some antimicrobial peptides for combating bacterial infections in mice.  These proteins have the 
potential to become an alternative to the over used antibiotics that have recently proved less 
effective as the number of resistant bacterial strains increases.   
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 2 Background  
2.1 Previous Antimicrobial Cloning Work  
Several other antimicrobial peptides have already been successfully cloned and expressed 
in bacterial systems.  Expression as a fusion protein is necessary to protect the product from 
degradation by cellular proteases as well as to prevent the product from exerting its toxic effects 
on the host cell.  Haught et al. (1998) successfully expressed the antimicrobial peptide P2 as a 
fusion protein with bovine prochymosin in E. coli.  P2 is a twenty three amino acid antimicrobial 
peptide that was developed synthetically.  When expressed, the fusion protein accounted for 
sixteen percent of the total cellular protein and formed inclusion bodies.  The inclusion bodies 
were purified by centrifugation, and cyanogen bromide was used to cleave the methionine linker 
that joined the two fusion partners.  Afterwards cation exchange HPLC followed by reversed 
phase HPLC were used for additional purification.  The activity of the recombinant product was 
found to be identical to a chemically synthesized control. 
Buforin II was expressed as tandem repeats fused to an acidic peptide in E. coli.  This 
method was adopted in an attempt to increase yields and minimize harmful antimicrobial 
activity.  The acidic protein was successful in neutralizing the basic charge of the peptide and in 
forming inclusion bodies.  Inclusion bodies were recovered by centrifugation and sonication, and 
resolubilized then treated with cyanogens bromide to separate the multimers from each other and 
the fusion protein.  Recombinant buforin II antimicrobial activity was compared with natural 
buforin II via radial diffusion assay.  They were found to have identical antimicrobial activity.  
(Lee et al. 1997) 
A final example of antimicrobial expression is the development of a system that could be 
used for expression of a variety of antimicrobial peptides.  The system results in the peptide of 
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 interest being produced as a fusion protein with the F4 polypeptide.  F4 promotes the formation 
of inclusion bodies which is essential.  Of numerous peptides produced with this system MSI-
344 was isolated and purified.  Cation exchange chromatography was used to isolate the fusion 
protein which was then cleaved with hydroxylamine to separate MSI-344 and the F4 peptide.  
Recombinant MSI-344 compared favorably with synthetic controls when assayed for activity. 
(Lee et al. 2000) 
 
2.2 Protegrins 
Protegrins are a small family of recently identified antimicrobial peptides, originally 
isolated from porcine neutrophils.  After synthesis, they are initially stored as precursors that 
remain inactive until hydrolyzed extracellularly by neutrophil elastase (Shi and Ganz 1998).   To 
date, five naturally occurring protegrins have been found, PG-1 to PG-5 (Steinberg et al. 1997).  
These peptides are cysteine-rich and show a significant amount of similarity among their peptide 
chains.  All are cationic and amphipathic, containing both polar and nonpolar amino acids 
(Steinberg et al. 1997; Cho et al. 1998).  Protegrins are between 16 and 18 amino acid residues in 
length.   This structure folds to form two antiparallel β−sheets connected by a hairpin turn which 
is stabilized by the presence of two cysteine disulfide bonds that typically occur between C6-C15 
and C8-C13 (Steinberg et al. 1997; Roumestand et al. 1998; Cho et al. 1998).  One study showed 
that these disulfide bonds are a key factor in protegrin microbicidal activity and a significant 
decrease was observed when one or both of these bonds were removed (Qu et al. 1997).     
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 2.2.1 The PG-1 Protein  
  The most widely studied of the natural protegrins is PG-1, which contains 18 amino acids 
and exhibits a broad range of antimicrobial activity.  Figure 3.1 shows the structure of this 
peptide.  This peptide has been assayed for activity against many representative strains of both 
gram positive and gram-negative bacteria, as well as some antibiotic-resistant strains.  It has also 
shown some antifungal and even antiviral activity (Yasin et al. 1996; Qu et al. 1997; Steinberg et 
al. 1997; Cho et al. 1998; Shi and Ganz 1998; Turner et al. 1998).  Under different experimental 
conditions, PG-1 has exhibited excellent antimicrobial activity in vitro against a variety of 
bacteria such as Escherichia coli, Listeria monocytogenes, Proteus vulgaris, and Bacillus 
subtilis.  B. subtilis was used in this work for assessing activity.  Typically, relatively low 
concentrations of the peptide are sufficient, since it has curious potency compared to certain 
other antimicrobial peptides (Yasin et al. 1996; Qu et al. 1997; Turner et al. 1998).  In one 
experiment, PG-1 was tested in vivo on mice that were inoculated with various types of bacteria. 
Steinberg et al. (1997) found that the mortality rate of the mice was significantly decreased after 
treatment with PG-1 relative to untreated mice.   
While not a serious public health problem yet, some strains of resistant bacteria have 
evolved.  The mechanisms of resistance involved range from a decrease in the net negative 
charge of the membrane to make it less electrically attractive, to physical pumping to remove the 
peptides (Peschel 2002).  Currently a synthetic analogue of PG-1 is undergoing Phase III clinical 
trials for FDA approval.  The compound being developed by Intrabiotics Pharmaceuticals, 
known as IB-367, is an oral rinse for use by cancer patients suffering from mucosistis.  The FDA 
has granted Fast-Track designation to the compound (www.intrabiotics.com).   
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 2.2.2 Mechanism of Antimicrobial Activity  
The exact mechanism by which protegrins inactivate various microbes has not yet been 
found but it is believed to operate by the toroidal pore model.  This means that groups of PG-1 
peptides come together and form a ring like structure to isolate a segment of the cell membrane.  
Once isolated, the two leaflets of the membrane fold in and connect to each other resulting in an 
unregulated pore.  Using radiolabeled lipids and radiolabeled PG-1 peptides in a synthetic bilayer 
and tracking shifts in their positions by NMR it was confirmed that PG-1 inserts across the 
membrane with its long axis parallel to the lipids.  Looking at Figure 3.1 it can be seen that at 
either end of the hairpin structure there is a concentration of cationic arginine residues while in 
the center there are hydrophobic amino acids (Leu, Tyr, Phe, Val).  This makes sense 
considering that the ends of the peptide would be interacting with the negatively charged 
phosphate head groups while the middle portion would be in contact with the hydrophobic fatty 
acid tails.  It is uncertain at this point if there are any earlier stages of multimerization before the 
formation of the isolating ring structure.  Further research is still required but this is currently the 
favored model for PG-1’s method of action (Yamaguchi et al.  2002).    
2.3 Bacillus subtilis 
The organism used for assaying the PG-1 peptide expressed from the artificial gene is 
Bacillus subtilis.  This bacterium is gram-positive and commonly found in nature, typically soil 
and straw samples.  It is aerobic and has the capability to form spores.  Bacteria in the genus 
Bacillus are characterized by their short, thick, rod-like structure.  They are motile due to the fact 
that they possess flagella.  This bacterium is considered a mesophile, since its growth is favored 
in the moderate temperature range, with optima between 20 and 45 degrees Celsius.  B. subtilis is 
a common bacterium for laboratory use because it is relatively easy to grow and typically not 
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 considered a pathogen (Prescott et al. 1999).  For these reasons, this bacterium was chosen for 
use in this thesis to assay PG-1.   
2.4 Pichia pastoris 
The yeast Pichia pastoris was the expression system initially chosen.  It is a commonly 
used system for the expression of proteins and more than 100 have successfully been produced 
by it (Higgins and Cregg 1998).  One of the many reasons that P. pastoris is used is that it 
genotypically resembles Saccharomyces cerevisae, which is a very well characterized system.  
This makes P. pastoris very easy to work with.  It is also quite inexpensive relative to other 
expression systems.  This type of yeast is easy to transform and grow in the laboratory.  P. 
pastoris utilizes glucose as a primary carbon source, which is inexpensive and easy to obtain.  
Methanol can be used as an alternate carbon source due to the alcohol oxidase (AOX1) gene. In 
cloning the alcohol oxidase promoter is used as the driving force behind cloned protein 
expression.  Adding methanol to a culture induces expression of whatever gene is downstream 
from the AOX1 promoter.  The cultures are capable of growing to high cell density that will 
improve the amount of protein being expressed.   The cultures are also quite resilient.  These 
reasons are why P. pastoris was initially chosen to express the synthetic PG-1 gene.   
2.5 T7 Expression System 
The pRSET vector is based on the T7 promoter expression system. Expression of the 
target genes cloned into the pRSET vector is induced by providing a source of T7 DNA 
polymerase in the host cell. This is accomplished by using the E. coli host BL21(DE3)pLysS 
which contains a chromosomal copy of the T7 DNA polymerase gene. The T7 DNA polymerase 
gene is under the control of the lacUV5 promoter which is induced by IPTG. T7 RNA 
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 polymerase is expressed upon induction and converts almost all of the host cell’s resources to 
transcribe the gene of interest which is downstream from the T7 promoter 
(www.invitrogen.com).  This system was later used due to difficulty with the P. pastoris system.   
 
3 Materials and Methods 
3.1 Design of the Synthetic PG-1 Gene 
The amino acid sequence of the antimicrobial protein PG-1 (GenBank accession number 
AAB27599.1) can be seen in Figure 3.1. 
 
Figure 3-1 Structure of PG-1.  This figure shows the amino acid sequence and the secondary structure of the 
PG-1 protein.  The solid bars between cysteine (C) residues represent disulfide bonds.  The asterisk indicates 
amidation at the C-terminus of the protein.   
 
From the amino acid sequence of PG-1, a DNA sequence was designed and optimized for 
expression in Pichia pastoris. This involved determining the codon bias of this organism.  The 
pim1 gene (GenBank accession number AJ006686) of P. pastoris was examined for this purpose.  
This particular gene is over one thousand seven hundred bases long and provides an adequate 
sample of the codon usage patterns of P. pastoris.  Each occurrence of the relevant codons 
corresponding to the amino acids in PG-1 in pim1 was noted.  The most frequently occurring 
codons were considered to be the preference of P. pastoris for the specific amino acids in the 
protein PG-1 and were used in the design of the nucleotide sequence (see Table 3-1).  The entire 
sequence of the proposed synthetic gene can be seen in Figure 3.2, in both single- and double-
stranded form. 
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A. 
5’–AGAGGGGGGAGATTATGCTATTGCCGGCGGCGGTTTTGCGTGTGCGTGGGGAGATGA-3’ 
 
B. 
5’ – AGAGGGGGGAGATTATGCTATTGCCGGCGGCGGTTTTGCGTGTGCGTGGGGAGATGA– 3’ 
3’ - TCTCCCCCCTCTAATACGATAACGGCCGCCGCCAAAACGCACACGCACCCCTCTACT– 5’ 
 
 
Figure 3-2 Nucleotide sequence of the synthetic PG-1 gene.  Part A shows the single stranded form of the 
coding region for the protein.  Part B shows the complete double stranded form of the nucleotide sequence. 
  
The protein-coding region of the gene was designed in the form of two overlapping 
oligonucleotides, as shown in Figure 3.3. 
 
 
5’ – AGAGGGGGGAGATTATGCTATTGCCGGCGGCGGTTTTGCGTGTGCGTGGGGAGATGA – 3’ 
3’ -  TCTCCCCCCTCTAATACGATAACGGCCGCCGCCAAAACGCACACGCACCCCTCTACT – 5’ 
 
 
Figure 3-3 Overlapping oligonucleotides.  The green highlighted region shows the oligonucleotides that were 
commercially synthesized. 
 
Table 3-1 Codon Bias of Pichia Pastoris.  The codons for the relevant amino acids corresponding to the 
protein PG-1 were counted in the pim1 gene and the most frequently occuring codons have been highlighted 
in yellow. 
 
Amino acid Codon Number of Occurences
Phe TTT 14
TTC 8
Leu CTT 9
CTC 4
CTA 4
CTG 7
TTA 9
TTG 13
Val GTT 8
GTC 5
GTA 2
GTG 9
Tyr TAT 15
TAC 4
Cys TGT 4
TGC 3
Arg CGT 1
CGC 2
AGA 11
AGG 2
CGA 5
CGG 2
Gly GGT 8
GGC 4
GGA 7
GGG 2  
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 The overlap was intentionally designed to be a GC rich region that allowed for added 
stability of the two nucleotides during their elongation.  The actual DNA sequences 
corresponding to the highlighted regions in Figure 3.3 were ordered from Sigma Genosys (The 
Woodlands, TX). 
3.2 Generation of the Archival Plasmid 
The two custom designed oligonucleotides were mixed in equimolar amounts along with  
2 mM dNTPs and H2O, and elongated using the Klenow fragment of DNA polymerase I (New 
England BioLabs, Beverly, MA).  The elongation reaction mix was incubated at room 
temperature for approximately one hour.  This resulted in the complete blunt ended double 
stranded sequence for the synthetic PG-1 gene, spg1.  Next, the plasmid pBluescript (Stratagene, 
La Jolla, CA) was treated with 20 units of the restriction enzyme EcoRV (New England 
BioLabs, Beverly, MA) and incubated at 37o Celcius for one hour to produce a blunt ended 
cloning site in the multiple cloning site (MCS) of the plasmid.  This digestion left the 5’ ends of 
the restriction site in the vector phosphorylated so it was unnecessary to phosphorylate the 
synthetic oligonucleotides.   
The enzyme T4 DNA ligase (New England BioLabs, Beverly, MA) was used to ligate the 
insert into the blunt EcoRV cloning site in pBluescript.  The ligation reaction was conducted 
following a ligation protocol adapted from Laboratory DNA Science (Bloom et al. 1996), which 
can be found in Appendix A.  The previously made elongation reaction was mixed with the 
EcoRV-digested pBluescript and 10X buffer for T4 ligase.  Four hundred units of the enzyme 
were added and the reaction mix was incubated at room temperature for three hours.   
The recombinant plasmid was transformed into TOPO Top 10F’ chemically competent E. 
coli cells obtained from Invitrogen (Carlsbad, CA), the protocol for which is in Appendix A.  
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 The cells were plated on LB agar plates with ampicillin (0.1 mg/ml), IPTG (0.5 mM), and X-gal 
(4 ug/ml).  The plasmid, pBluescript, contains the alpha fragment of the lac Z gene as well as a 
gene that confers resistance to the antibiotic ampicillin.   These features allowed for easy 
detection of plasmid uptake by the host cells and selection of recombinants.  The bacterial 
transformants containing the recombinant construct grew as white colonies.  Although the insert 
is only fifty-seven bases it still succeeded in disrupting the alpha fragment of the lac Z gene, due 
to an in frame stop codon at the 3’ end.  In this instance, the stop codon was very helpful because 
inserts smaller than approximately 200 bases usually fail to completely disrupt the function of 
the alpha fragment, making recombinant selection difficult.  Liquid cultures of randomly selected 
white colonies containing 5 ml L broth (5 g Bacto Tryptone, 2.5 g Yeast Extract, 0.25 g NaCl for 
500 ml) and 5 µl ampillicin (100 mg/ml) were prepared and incubated overnight at 37o Celcius.  
The plasmids were isolated from the cells using standard plasmid minipreparation techniques, 
the protocol for which can be found in Appendix A.  Samples of the isolated plasmids were run 
on a 1% agarose gel.  
3.2.1 Confirmation of spg1 Insert 
 
Once isolated, the plasmids were analyzed for the presence of an insert into the MCS.  This 
was done by performing a polymerase chain reaction (PCR) across the MCS using 50 pmol each 
of the M13 Forward and M13 Reverse primers from Sigma Genosys (The Woodlands, TX), 
which flank the multiple cloning site of pBlueScript.  Two and one-half units of Taq DNA 
Polymerase (Promega, Madison, WI) were used to catalyze the reaction.  See Appendix A for the 
complete PCR protocol.  Samples of the PCR reaction products were run on a 1.5% gel and 
visualized by ethidium bromide staining, see Figure 4.2. 
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 3.2.2 Sequencing of Insert 
 
Once the recombinant plasmid was confirmed to contain an insert, it was sequenced to 
ensure that it was still intact and contained the correct sequence.  This was done using ABI 
sequencing technology.  See Appendix A for exact protocol.    
 
3.3 Extension of spg1 Insert 
3.3.1 Design of Longprimer and Shortprimer 
 
Once the presence of the insert was successfully confirmed, the next step in the process 
was to perform PCR on the archival plasmid using specially designed primers.  Primers were 
designed to add restriction sites and secretion signals to the ends of the amplicon and can be seen 
in Figure 3.4.   They were ordered from Sigma Genosys (The Woodlands, TX).  The 
“longprimer” would add an XhoI restriction site and a Kex 2 secretion signal to the 5’ end of the 
amplification product.  The “shortprimer” would add an EcoRI site to the 3’ end of the amplicon.  
PCR was performed using 50pmol of each primer in addition to 2.5 units of Taq DNA 
polymerase (Promega, Madison, WI). 
 
 
 
 
A. Longprimer 
 
5’ – ACA CTC GAG AAA AGA GAG GCT GAA GCT AGA GGG GGG AGA TTA TGC T – 3’ 
       XhoI              Kex2       Ste 13 signal 
 
B. Shortprimer 
5’ – CGG AAT TCT CAT CTC CCC ACG CAC AC - 3’ 
   EcoRI 
Figure 3-4 Extension Primers.  Part A shows the sequence of the longprimer designed to extend the 5’ end of 
the coding region of spg1 and add an XhoI restriction site and a Kex2 secretion signal (yellow and green 
highlighted regions, respectively).  Part B shows the sequence of the shortprimer designed to extend the 3’ 
end of spg1 and add an EcoRI restriction site (blue highlighted region). 
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 3.3.2 PCR Reactions with Extension Primers 
 
A PCR reaction was performed on the archival plasmid, pAM5 using 50 pmol each of the 
extension primers and 2.5 units of Taq polymerase.  A dummy reaction was also set up using the 
same reagents except substituting water for the polymerase.  The reaction products were then run 
on a 1.5% gel.  The full-length extension product that would have resulted from a successful 
PCR with longprimer and shortprimer can be seen in Figure 3.5. 
 
 
 
5’ – ACACTCGAGAAAAGAGAGGCTGAAGCT AGAGGGGGGAGATT ATGCTAT TGCCGGCGGCGGTT TTGCGTGTGCGTGGGGAGATGA – 3’ 
3’ – TGTGAGCTC TT TTCTC TCCGAC TTC GATC TCCC CCC TCT AATACGATAACGGCCGCCGCCAAAACGCACACGCACCCCTCTAC T – 5’ 
Figure 3-5 Full length Extension Product.  This is the sequence of the extended spg1 gene containing the 
appropriate restriction sites and secretion signal. 
 
3.4 PCR with Combination Primers 
To examine the function of the longprimer and shortprimer individually, each was 
combined with one of the M13 primers.  The longprimer was mixed with the M13 Reverse and 
the shortprimer with M13 Forward.  pAM5 and 50 pmol each of longprimer and  M13 Reverse 
primer were mixed in a PCR reaction with 2.5 units of Taq polymerase (Promega Madison, WI).  
The same was done with the shortprimer and the M13 Forward primer.  The following PCR 
reactions were also performed: pAM5, 50 pmol each of longprimer and short primer, and 2.5 
units of Taq polymerase; pAM5, 50 pmol each of M13 Forward and M13 Reverse primers, and 
2.5 units of Taq polymerase; pBluescript, 50 pmol each of M13 Forward and M13 Reverse 
primers, and 2.5 units of Taq polymerase.  Samples from each of the PCR reaction products were 
run on a 1.5% agarose gel and can be seen in Figure 4.5. 
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 3.5 Attempted Construction of the P. pastoris Expression Vector 
 Had a PCR product been obtained from the reaction with the long and short primers the next 
step would be to put this product into the pPIC9 expression vector.  Hypothetically the 
longprimer/shortprimer PCR product and the pPIC9 vector would have been separately double 
digested with the appropriate restriction enzymes and then mixed and joined together with T4 
ligase.  The result of this would have been the directional cloning of the insert into the multiple 
cloning site.   
3.6 Construction of pRSET Expression Vector 
Two custom designed oligonucleotides utilizing the naturally occurring PG-1 gene 
sequence were mixed in equimolar amounts in an annealing solution of 100 mM Tris and 150 
mM NaCl at pH 7.4 and allowed to incubate at room temperature for ten minutes.  This resulted 
in the complete double stranded sequence for the synthetic PG-1 gene with the necessary 
restriction overhangs.  Next, the plasmid pRSET A (Invitrogen, Carlsbad, CA) was treated with 
20 units each of the restriction enzymes EcoRI and XhoI (New England BioLabs, Beverly, MA) 
and incubated at 37o Celcius for one hour.  This digestion left the 5’ ends of the restriction site in 
the vector phosphorylated so it was unnecessary to phosphorylate the synthetic oligonucleotides.  
The sequence of the two synthetic genes is as follows:  
5’-TCGAGAGGGGAGGTCGCCTGTGCTATTGTAGGCGTAGGTTCTGCGTCTGTGT 
CGGACGAGGATGAG-3’        
5’-AATTCTCATCCTCGTCCGACACAGACGCAGAACCTACGCCTACAATAGCACA 
GGCGACCTCCCCTC-3’ 
The enzyme T4 DNA ligase (New England BioLabs, Beverly, MA) was used to ligate the 
insert into the doubly digested pRSET A vector.  The ligation reaction was conducted following 
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 a ligation protocol adapted from Laboratory DNA Science (Bloom et al. 1996), which can be 
found in Appendix A.  The previously made annealing reaction was mixed with the double 
digested pRSET A and 10X buffer for T4 ligase.  Four hundred units of the enzyme were added 
and the reaction mix was incubated at room temperature for three hours.   
The recombinant plasmid was transformed into TOPO Top 10F’ chemically competent    
E. coli cells obtained from Invitrogen (Carlsbad, CA), the protocol for which is in Appendix A.  
The cells were plated on LB agar plates with ampicillin (0.1 mg/mL) and allowed to incubate 
overnight at 37 degrees Celcius.   
3.6.1 Confirmation of Insert 
After isolation, the plasmids were analyzed for the presence of an insert into the MCS.  
This was done by performing a polymerase chain reaction (PCR) across the MCS using 50 pmol 
each of the T7 Promoter and T7 Reverse primers from Sigma Genosys (The Woodlands, TX), 
which flank the multiple cloning site of pRSET A.  Two and one half units of Taq DNA 
Polymerase (Promega Madison, WI) were used to catalyze the reaction.  See Appendix A for the 
complete PCR protocol.   
3.6.2 Sequencing of pRSET A Insert 
Once the recombinant plasmid was confirmed to contain an insert, it was sequenced to 
ensure that it was still intact and contained the correct sequence.  The sample was sent to 
University of Massachusetts Medical School to be sequenced.  
3.7 Expression and Purification  
Plasmids with the correct insert were isolated and then transformed as described above into 
codon competent BL21:DE3.  Four different plasmids were isolated and transformed to 
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 minimize the chance of having an unexpressive plasmid.  A single colony was taken and 
inoculated into a 5 ml culture containing 50 ug/ml ampicillin and 35 ug/ml chloramphenicol and 
grown overnight at 37 degrees Celcius.  These initial cultures were then added to either 25 ml or 
100 ml of LB broth with antibiotics and grown to an OD600 between 0.4 and 0.6 at which point 
IPTG was added to a final concentration of 1 mM to induce expression.  The cultures were 
incubated for one hour post induction to allow adequate time for expression.  Harvesting began 
by centrifuging the cultures at 10,000 x g for fifteen minutes.  The pellet was then resuspended in 
50 mM sodium phosphate buffer at pH 7.0 with 300 mM NaCl, 2 ml buffer for every 25 ml of 
culture, and sonicated with four one-minute passes at power setting four on a Sonifer Cell 
Disruptor (model W185) sonicator.  Afterwards the suspension was centrifuged at setting six in 
an IEC clinical centrifuge to pellet insoluble material.  The insoluble material was washed twice 
with a five percent solution of Triton X-100.  Further centrifugation pelleted any remaining 
insoluble material which was then resuspended in 50mM sodium phosphate buffer at pH 7.0 with 
300 mM NaCl and 6M guanidine HCl.  The supernatant from the initial cell harvest and the 
resolubilized material were subjected to batch flow chromatography.  An aliquot of Clontech 
Talon Immobilized Metal Affinity Chromatography (IMAC) resin was equilibrated in the 
appropriate buffer and then 50 µl of resuspended resin was added to each tube and incubated for 
one hour.  Afterwards the tubes were centrifuged on setting two on an IEC centrifuge to pellet 
the resin and then washed twice with the sodium phosphate buffer.  The supernatant was 
removed and SDS-PAGE sample buffer was added to the resin to elute any bound protein.  
These samples were then run out on a SDS-PAGE gel. 
After confirmation of protein expression in fresh cultures by anti-his tag Western blot an 
alternative purification scheme was adopted.  All new samples believed to have protein were 
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 pooled and sonicated.  Insoluble material was spun down and resuspended in 50 mM sodium 
phosphate buffer at pH 7.0 with 300 mM NaCl and 6M guanidine HCl.  No detergent wash was 
performed.  The soluble and insoluble fractions were each put through a mixed batch/gravity-
feed chromatography protocol with 0.5 ml Clontech Talon IMAC resin and eluted with 10 mM 
sodium phosphate buffer with 300 mM NaCl at pH 5.0.  Batch chromatography was performed 
initially with one hour incubation and then this resin was loaded onto a mini column for elution.  
The resulting fractions were adjusted back to pH 7.0 with sodium hydroxide then assayed for 
antimicrobial activity via radial diffusion assay.   
3.8 SDS-PAGE gel analysis 
 Once isolated the above samples were run on a non-reducing SDS-PAGE gradient gel to 
look for evidence of expression.  The resolving gel was cast with a 10 – 20% gradient of 
acrylamide with methylene bis-acrylamide and the stacking gel was five percent.  The 
acrylamide used was 40%T:5%C.  20 µl of each sample was loaded onto the gel, which was run 
at 50V for two hours.  Staining was performed with Coomassie blue for at least eight hours.  
Destaining was done with repeated incubations in a solution of ten percent glacial acetic acid and 
ten percent methanol. 
3.9 RNA Isolation and Analysis 
RNA analysis and RT-PCR were used to attempt to determine if the protein was being 
expressed at minimal levels.  Total cellular RNA was isolated using Invitrogen’s Trizol reagent.  
This product is a mixture of phenol and guanidine thiocyanate for cell lysis and RNA extraction.  
The manufacturer’s protocol was followed without variation and will be described briefly here.  
A 5ml aliquot of cells was centrifuged at 10,000 x g and the pellet resuspended in 1 ml of Trizol 
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 reagent.  After a brief incubation 0.2 ml of chloroform was added and the samples vigorously 
shaken then centrifuged to enhance phase separation.  The aqueous phase was then removed and 
mixed with isopropanol, incubated, and centrifuged to precipitate the RNA.  Seventy-five 
percent ethanol was used to wash the pellet once, after which it was resuspended in DEPC-
treated RNAse free water.   
Ambion’s RETROScript kit was used to perform RT-PCR on the RNA isolates.  The RT-
PCR was performed according to the manufacturer’s protocol without modification.  Reverse 
transcription (RT) primer one was internal to the PG-1 gene: 5’-
CGCCTACAATAGCACAGGC-3’.   RT primer 2 was positioned at the end of the putative 
mRNA: 5’-CGGTGGCAGCAGCCAACTCAG-3’.  The PCR primer sequence was:  5’-
GACCACAACGGTTTCCCTCT -3’. 
RNA samples were found to have contaminating DNA.  This was discovered by 
performing PCR following the recipe in Section 3.2.1 with primers that amplified across an 
unexpressed region of pRSET A.  The primer sequences are as follows: 5’-
CGCTCAAGTCAGAGGTGGCG-3’,    5’-CGTGCACACAGCCCAGC-3’        
  Removal of the contaminating DNA was attempted using acid phenol extraction 
followed by the DNA-free DNase kit from Ambion.  The procedure for the DNA-free kit was 
performed according the manufacturers protocol without variation.  DNA removal did not appear 
to be successful and will be discussed in Sections 4.7 and 5.5.   
3.10 Immunoblotting 
After running the culture samples on an SDS-PAGE gel the proteins were then transferred 
to PVDF membrane using a Transphor semi-dry transfer unit.  The membrane was rinsed in 50 
mM Tris, 0.2 M NaCl  buffer (Buffer 229) at pH 7.4 for ten minutes.  Blocking was done for 
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 twenty minutes using the same buffer as above with five percent non-fat dry milk added.  One-
fifth vols of a 1:100 dilution, in blocking buffer, of the primary anti-his antibody (Santa Cruz 
Biotech, Cat No. sc-803) was added to the blocking solution and allowed to incubate for two 
hours at room temperature.  The membrane was then rinsed with Buffer 229 w/0.05% Tween 20, 
washed for five minutes, and then again for twenty minutes.  A second blocking was performed 
for twenty minutes in Buffer 229 w/ .05% Tween and 5% milk after which 10 µl of secondary 
antibody (anti-rabbit HRP conjugate: Cell Signaling Tech) was added to the solution and 
incubated for one hour at room temperature.  After this incubation the rinse and wash mentioned 
above were repeated.  The membrane was then soaked with the chemiluminescent substrate for 
one minute and then exposed to X-ray film.  
3.11 Radial Diffusion Assay 
The radial diffusion assay was used to assay the biological activity of antimicrobial 
samples.  Ten milliliters of 10 mM sodium phosphate buffer at pH 7.4 was mixed with 0.1 g 
agarose and 0.3 mg of tryptic soy broth powder.  This mixture was heated and allowed to cool to 
~ 43 degrees Celcius at which time 200 µl from a log phase B. subtilis culture was added to the 
gel.   The mixture was poured onto a petri plate and allowed to solidify.  Wells were then 
punched into the agar and 10 µl of a 2.5 mg/ml solution of PG-1 and culture samples were put 
into their appropriate wells.  The plate was then allowed to incubate for three hours after which 
an overlay gel consisting of 10 ml 10 mM pH 7.4 phosphate buffer, 0.1 g agarose, and 0.6 mg 
tryptic soy broth powder was cast.  As described above, it was heated and allowed to cool then 
poured over the underlay gel.   
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4 Results 
4.1 Isolation of pAM5 
  The archival plasmid was named pAM5.  Agarose gel electrophoresis of the uncut 
plasmid minipreparations confirmed the presence of a plasmid as seen in Figure 4.1. 
Figure 4-1 Plasmid minipreparation gel.  Lane 7 (from left) is the control lane containing pure uncut 
pBluescript.  Lanes 1-6 (from left) contain samples of plasmid isolated from various colonies of transformed 
cells.  The gel clearly shows these plasmids are running equally with the pBluescript control.  
4.2 Confirming the Presence of the Insert and Proper Sequence 
 
 Polymerase chain reaction (PCR) was performed on the hybrid plasmid for confirmation 
of an insert.  There was a detectable size difference between the amplification products of the 
miniprep samples and the control, unaltered pBlueScript (see Figure 4.2).  The insert was then 
sequenced using ABI sequencing technology (see Appendix A for procedure).  This technique 
was also used to screen for recombinant plasmids when constructing the pRSET A expression 
vector (data not shown).   
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 Figure 4-2 PCR Across the MCS.  The above gel photo shows a PCR of the multiple cloning site (MCS) of 
recombinant pBluescript plasmids (lanes 1-4) and unaltered pBluescript (lane 6 from left) using M13 forward 
and reverse primers.  Lane 1 is a linear size marker.  This gel indicates that the recombinant plasmids 
contain an insert (~200bp) because of the noticeable size difference between them and unaltered pBluescript 
(~150bp).   
After the plasmid containing the correct sequence of the insert had been established, a 
freezer stock was prepared of the cells from which the plasmid was isolated.  Figure 4.3 displays 
the sequence data.   
 
        EcoRV 
 M13 R: 5’- TTCGAT TCA TCT CCC CAC GCA CAC GCA AAA CCG CCG CCG GCA ATA GCA TAA TCT CCC CCC TCT ATCAAG –3’ 
                                                                                   EcoRV 
 
                      EcoRV 
M13 F: 5’- CTTGAT AGAGGG GGG AGA TTA TGC TAT TGC CGG CGG CGG TTT TGC GTG TGC GTG GGG AGA TGA ATCGAA –3’ 
                                                                                                                                                                                                                   EcoRV 
 
Figure 4-3 Sequencing Data.  The yellow highlighted regions designate the EcoRV restriction site.  The data indicates 
that the plasmid sequenced contained the complete and correct sequence of the spg1 gene.  The M13 reverse primer gives 
the sequence of the bottom strand while the forward primer gives the sequence of the top strand. 
 
4.3 Results of PCR with Long and Short Primers 
PCR with the long and short primers was unsuccessful.  Although a strong band was visible 
in the LS lane, this was the only band seen.  This made it impossible to determine if the bands 
represented an amplification product or left over primer.  Given that this was the only band seen 
in this lane besides the vector band (not shown), and that it ran equidistant to the primer band in 
the dummy lane, the band was attributed to the long and short primers included in the reaction 
mix.  Figure 4.4 shows an example of a gel from one of the PCR runs.   
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Figure 4-4 PCR using longprimer and shortprimer.  Lane 2 (LS) shows the PCR reaction of the archival 
plasmid using longprimer and shortprimer.  Lane 3 (D) shows the dummy PCR containing the same reagents 
as LS except for the substitution of the enzyme with water.  No amplification product is seen in the LS lane; 
the band seen is a result of the primers used.  There is no difference seen between the LS and the D lanes.  
The PCR product, if had been seen, would run at ~80bp.     
 
4.4 Mixing of M13 Primers with Long and Short Primers 
After initial difficulties with the long and short primers, another PCR was performed using 
those primers in combination with the M13 Forward and Reverse Primers.  The gel in Figure 4.5 
shows that the long and short primers do work individually to produce a product but for some 
reason fail to function when mixed together, as seen in the LS lane, reinforcing the results shown 
in Figure 4.4.    Based on the results of the PCR described in Section 3.4 and seen in Figure 4.5 
Lane 5 (FR), it was hypothesized that one or both of the M13 primers was hybridizing with the 
insert contained in the archival plasmid, pAM5.  The sequences of the M13 Forward and Reverse 
primers and the spg1 insert were analyzed for possible hybridization sites for the primers.  The 
pairing between at least three bases on the 3’ end of either primer with part of the insert was the 
basic criterion used in this analysis.   It was found that the M13 Reverse primer could possibly 
base pair to one strand of insert in this fashion as shown in Figure 4.6.  
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To test the hypothesis that the M13 Reverse primer can hybridize to the spg1 insert, a PCR 
reaction was set up that contained the archival plasmid pAM5, 100 pmol of the M13 Reverse 
primer, and 2.5 units of Taq polymerase.  The results of this reaction can be seen in Section 4.5 
in Figure 4.6. 
Figure 4-5 PCR with Mixed Primers.  In order to test the function of the designed extension primers, longprimer and 
shortprimer, each were combined with another primer that flanks the MCS of the plasmid.  LR indicates the reaction 
containing pAM5 and the longprimer and M13 Reverse primer.  SF indicates the reaction containing pAM5 and the 
shortprimer and M13 Forward primer.  LS indicates the reaction containing pAM5 and the longprimer and shortprimer.  
FR indicates the reaction containing pAM5 and the M13 Forward and Reverse primers.   pBlue-FR indicates the reaction 
containing unaltered pBluescript and the M13 Forward and Reverse primers.  Amplification products are seen in the LR 
and SF lanes, indicating that the primers are functional when used with other primers, but not when combined together, 
as indicated by the LS lane where no amplification product is seen.  Multiple amplification products are seen in the FR 
lane.  
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 4.5 Complications with the M13 Reverse Primer 
From the reactions described in Section 3.4 and 3.5, the results seen in Figure 4.6 were 
obtained.  Multiple bands were seen in the R lane of the gel indicating unexpected hybridization 
of the M13 Reverse primer to the insert region.  The lower diagram in Figure 4.6 shows points of 
hybridization between the M13 Reverse primer and the spg1 gene.   
Figure 4-6 PCR using only M13 Reverse Primer.  R indicates the reaction containing pAM5 and the M13 Reverse 
primer.  Multiple bands are seen in the R lane suggesting that this primer has more than one priming site on the plasmid, 
including one in the insert region.  This diagram below this caption shows the sequences of the M13 Reverse 
primer and the bottom strand of the spg1 coding region and the possible base pairing that could occur 
between them as indicated by the vertical lines.      
 
M13 Reverse              5’ –AGG AAA CAG CTA TGA CCA T G– 3’ 
                                      |      |        |                |  |        |   |   | 
spg1 Bottom strand              3’ –TC T  CCC CCC  TCT AAT A C G ATA ACG GCC GCC GCC AAA ACG CAC ACG CAC CCC TCT- 5’ ACT– 5’
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4.6 SDS-PAGE Analysis 
 SDS-PAGE analysis of cultures prior to any processing revealed no evidence of 
expression. Figure 4.7 shows whole cell lysate from a 100 ml culture.  Close examination reveals 
that all lanes are identical regardless of whether they were induced or not.  If significant 
expression had occurred a prominent band should have been visible within the same size range 
as the Cytochrome C standard.  Figure 4.8 shows the results of whole cell lysate gel analysis 
from a separate 25 ml culture grown following the standard protocol.  Again, no significant 
difference can be seen between the lanes.  Through the various purification procedures, SDS-
PAGE analysis was never able to visualize any expression of the protein.     
  
 
Figure 4-7 Gel showing the whole cell lysates.  2-NI is an uninduced PG-1 clone while 2, 26, and 50 were induced with 
1mM IPTG.  Expression of the target protein would have produced a prominent band with a MW of ~5.5kD running 
slightly below the Cytochrome C standard.  
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Figure 4-8 A second gel showing results from whole cell lysates of a 25ml culture.  No significant difference can be seen 
between the uninduced (2NI) and induced lanes (2, 26, 50). 
 
4.7 Analysis of RT-PCR 
Use of RT-PCR ran into an unexpected problem in the form of contaminating DNA from an 
unexpected source.  Although initial attempts showed bands in all lanes with the appropriate 
sizes, Figure 4.9, later experiments showed the presence of contaminating DNA.  After this 
initial RT-PCR, work was done to remove any contaminating DNA.     
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Figure 4-9 Initial attempt at RT-PCR.  Overall the bands are where they should be.  The 3’MCS product is 
slightly larger than the internal PG-1 product.  This is because the latter use a primer internal to the PG-1 
gene that is upstream from the terminal 3’MCS primer.  There is also a signal of roughly equal intensity in 
the uninduced lanes.  The 3’MCS product is running at ~200bp while the Internal PG-1 product is at ~150bp.     
 
 After two acid phenol extractions and three DNase treatments the contaminating signal was 
still present after PCR.  Eventually it was found that the contamination was in the Taq 
polymerase stocks themselves.  These are commercially available enzymes purchased from 
outside distributors.  The significance of this will be explained in the discussion section.  Figure 
4.10 shows the results of PCR done on several commercial enzymes using primers across the 
unexpressed ORI region of the plasmid.  Some commercial enzymes were found to be 
contaminated with bacterial DNA.   
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Figure 4-10 This figure shows a PCR reaction using the DNA primers described in section 3.10.  None of the 
lanes have any intentionally added template.  Lane C is a control which also lacks any form of polymerase.  
Lanes 1-6 are various commercially available DNA polymerases.  While there are other visible bands it is 
clear that one signal predominates at 200bp.   Lanes 2 and 3 show no PCR products of any kind.   
 
4.8 Immunoblot Analysis 
After gel analysis and RT-PCR proved unsuccessful, immunoblotting using anti-his 
antibody was used to look for evidence of expression.  The procedure was performed as outlined 
in methods.  Figure 4.11 shows a blot using whole cell lysates from a 25 ml culture series.  The 
bottom-most row of bands on this gel clearly shows a difference in intensity between the 
uninduced lane 3, and lanes 4, 5, and 6 that were induced.  The bands of interest are running in 
the expected size range of approximately 5.5kD.  
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Figure 4-11 Immunoblot for His-Tagged Proteins on 25 ml cultures.  Lane 1 is a his-tagged 88kD control 
protein.  Lane 2 is whole cell lysate from a culture which is known to express a his tagged protein at ~55kD.  
Lane 3 is an uninduced PG-1 clone.  Lanes 4-6 are induced PG-1 clones.  Comparing lanes 4-6 to lane 3 in the 
size range of interest (~5.5kD) clearly shows that the intensity of the induced lanes is greater than that of the 
uninduced.   
 
Figure 4.12 also shows a similar result to Figure 4.11.   The layout of the lanes is identical.  
Figure 4.12 resulted from an immunoblot performed on whole cell extracts from a 100 ml 
culture.     
 
Figure 4-12 Immunoblot for His-Tagged Proteins on 100 ml cultures.  Lane 1 is a his-tagged 88kD control 
protein.  Lane 2 is whole cell lysate from a culture which is known to express a his-tagged protein at ~55kD.  
Lane 3 is an uninduced PG-1 clone.  Lanes 4-6 are induced PG-1 clones.  Comparing lanes 4-6 to lane 3 in the 
size range of interest (<10kD) again shows bands in he induced lanes (especially 5 & 6) and almost nothing in 
the uninduced lane. 
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Figure 4-13 Immunoblot for His-Tagged Proteins on other 25 ml cultures.  Lane 1 is a his-tagged 88kD 
control protein.  Lane 2 is whole cell lysate from a culture which is known to express a his-tagged protein at 
~55 kD.  Lane 3 is an uninduced PG-1 clone.  Lanes 4-6 are induced PG-1 clones.  Comparing lanes 4-6 to 
lane 3 in the size range of interest (<10kD) shows bands present in the induced cultures that are not present in 
the uninduced lane.  While the multiple banding seen here is somewhat undesirable it still supports the 
hypothesis that there is a protein in the induced cultures that is present in greater quantities than in the 
uninduced lane. 
 
Figure 4.13 is a blot from a second 25 ml culture set up identically to the previous two.  Overall 
the three blots show solid evidence that induction is occurring and that a his-tagged protein of 
approximately the correct size, 5.5 kD, is being produced. 
4.9 Radial Diffusion Assays 
Radial diffusion assays were performed on lysates from 25ml cultures in order to look for 
biological activity.  Figure 4.14 shows a radial diffusion assay performed as outlined in Methods 
except that culture wells were loaded with 10 µl of lysate four times in order to increase the 
protein concentration.  Clear areas radiating out from a well indicate antimicrobial activity as 
with the PG-1 positive control obtained from Dr. Robert Lehrer of UCLA.  Whole cell lysates 
from PG-1 clones showed no antimicrobial activity even with sample stacking.   
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Figure 4-14 Radial diffusion assay.  The central well is loaded with a pure PG-1 sample at 2.5 mg/ml.  Well 
2NI contains lysate from an uninduced PG-1 clone.  Wells 2, 26, and 50 contain lysate from induced PG-1 
clones.   Each culture well received a total of 40 µl of lysate.   
 
Figure 4.15 shows a radial diffusion assay using a serial dilution of pure PG-1 stock.  The well at 
the twelve o’clock position contains PG-1 at a concentration of 2.5 mg/ml.  The concentration 
decreases by a factor of ten with each well going clockwise.  The plate shows that the assays 
lower limit for PG-1 detection is about 2.5 µg/ml (well number 4).   
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Figure 4-15 Radial diffusion assay with serial dilutions of control PG-1.  Well 1 = PG-1 at 2.5 mg/ml.  Well 2 = 
0.25 mg/ml.  Well 3 = 0.025 mg/ml.  Well 4 = 2.5 µg/ml.  Well 5 = 0.25 µg/ml.  The dilution series shows that 
the lower limit of the assays sensitivity seems to be about 2.5 µg/ml.  Below this concentration the assay may 
not be able to detect the presence of PG-1. 
 
 Radial diffusion assays using PG-1 purified by IMAC from culture extracts did show 
signs of antimicrobial activity (Figs. 4.16 and 4.17).  As above, each well was loaded four times 
with 10 µl of of sample to increase the protein concentration.  The diameter of the clear zone 
seems to indicate that the protein concentration in the well was slightly above 2.5 µg/ml.  See 
Figures 4.16 and 4.17. 
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Figure 4-16 Radial diffusion assay with culture lysates purified by IMAC.  SS-E1, SS-E2, IB-E1, and IB-E2 
are elution fractions.  The left hand picture shows the entire plate while the right hand picture is a close up of 
an elution fraction SS-E1 which produced a visible clear zone.   The central well is loaded with pure PG-1 
control at a concentration of 2.5 mg/ml.   
 
Figure 4-17 A second radial diffusion assay laid out similarly to Figure 4.16  Notice the elution buffer (see 
Section 3.7) well (EB) which shows no signs of a clear zone.  This gives further indication that PG-1 in the 
lysates is responsible for the clear zones.   
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5 Discussion 
5.1 Plasmid Minipreparation Analysis 
Plasmid minipreparations were run out on 1% agarose gel against a control lane with 
unaltered pBluescript.  Figure 4.1 clearly shows that the isolated plasmids are running 
equidistant with the control lane.  Our insert of only fifty-seven bases would not produce a 
noticeable difference in the migration of the entire plasmid, so this was not a factor to consider 
when confirming the presence of the plasmid.  Thus, we would expect the isolated recombinant 
plasmids to migrate at the same rate as pBluescript.  This also means that this gel is not useful for 
confirming the presence of the actual insert.   
5.2 Analysis of the MCS of pAM5 and Confirmation of the Sequence 
PCR across the MCS of pBluescript was used to confirm the presence of an insert.  This 
method was used because fifty-seven bases would not produce an observable size difference or 
affect migration in a 2961 base pair plasmid.  In a plasmid that does not contain an insert, PCR 
across the MCS using the M13 forward and reverse primers gives a PCR product of 227 bases.  
The presence of the insert increases the size of the fragment to 284 bases, which is a twenty five 
percent increase in the size of the fragment.  An increase of this magnitude is easily detectable on 
a two- percent agarose gel as shown in Figure 4.2.  The slower band in each lane represents a 
PCR fragment that contains the insert of interest.  From this gel it was possible to determine the 
best candidate for sequencing. 
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 Sequencing of the plasmid from which the strongest PCR signal was obtained, again 
confirming the presence of the insert and showed that its sequence was completely intact.  This 
plasmid was named pAM5, and a freezer stock of these cells was made and stored.   
5.3 Analysis of P. pastoris Expression Vector Construction Attempt 
5.3.1 PCR Using Designed Extension Primers  
 
Based on the results of various PCR reactions (see Figures 4.4 and 4.5), it could not be 
concluded that an amplification product was generated from the extension primers and the spg1 
insert.  Even though when individually paired with an M13 counterpart (see Section 3.4) 
amplification was seen, the longprimer and shortprimer appeared to be defective when used 
together.  Repeated PCRs using the longprimer and shortprimer failed to produce amplification 
products and, therefore, these particular primers should not be used in future attempts.   
5.3.2 Ligation into Expression Vector 
 
 The ligation into the expression vector was unsuccessful because the vector we were given 
was not the vector outlined in Section 3.6 and in the Invitrogen catalogue.  It actually had one 
EcoRI site between two XhoI sites.  Double digestion of this vector produced a MCS, which had 
two XhoI compatible ends as opposed to one EcoRI end and one XhoI end.  Extensive time was 
spent attempting to determine the cause of our problems with ligation that eventually lead to the 
discovery of the vectors true design.   
5.3.3 Hybridization of M13 Reverse Primer  
 
Another unforeseen problem that arose was that the M13 reverse primer was believed to be 
hybridizing with the insert in the archival plasmid, pAM5, in addition to its native priming site.  
In Figure 4.5, multiple amplification products are seen in the FR lane.  This reaction mix 
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 contained pAM5 and the M13 Forward and Reverse primers.  The control for this reaction is 
shown in the pBlue-FR lane, which contains the same primers as the FR reaction but using 
unaltered pBluescript as the template instead of the archival plasmid.  The only difference 
between the plasmids used in those reactions is the presence of the spg1 insert.  The multiple 
amplification products seen in the FR lane of Figure 4.6 therefore suggest that one or both of the 
primers may have hybridized with our insert, amplifying alternate regions of the plasmid.  
Analysis of the insert and primer sequences showed that the M13 Reverse primer could possibly 
do just that.  This was confirmed by the PCR using only the M13 Reverse primer, shown in 
Figure 4.6.  As a result of this, and possibly other hybridizations of this primer to the insert 
region, multiple amplification products are seen. 
5.4 PG-1 Expression 
While not expressed in abundant quantities, the immunoblots show that the his-tagged PG-1 
protein is present.  There are a variety of possible explanations why the expression was weak.  
The most likely one is the fact that PG-1 is a toxic protein.  Although it is being produced as a 
his-tagged fusion protein this may not fully control its toxic effects.  Depending on how the 
protein is folded it still may be able to insert itself across the membrane and exert some toxic 
effects.  Radial diffusion assays were found to be functional down to 2.5 µg/ml of protein.  
Whole cell lysates showed no signs of PG-1 activity when assayed.  IMAC was used to attempt 
to isolate his-tagged PG-1.   
Radial diffusion assays performed on these samples show signs of antimicrobial activity.   
Based on the diameter of the clear zone it appears that the concentration of PG-1 in the well was 
approximately 2.5 µg/ml.  The fact that the wells were loaded four times over means that the 
actual concentration of PG-1 in the elution fraction may have been roughly 0.625 µg/ml.    
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 5.5 RT-PCR 
One interesting discovery made during this thesis is that a fair number of commercially 
available Taq DNA polymerases are contaminated with plasmid DNA.  Most likely this DNA is 
left over from the purification process.  This was realized while attempting to use RT-PCR to 
search for plasmid expression.  As a control for contaminating DNA in the RNA preparations it 
is necessary to have primers that amplify across an unexpressed region.  The only available 
region for this on a plasmid is the origin of replication.  After two separate acid phenol 
extractions and three DNase treatments contaminating DNA was still present.  It was suggested 
the homemade Taq polymerase, cloned in our own lab, used may have plasmid contamination.  
A commercial Taq was used and the signal was still detected.  Eventually PCR was performed 
with all components added except any form of a template.  The questionable signal was again 
detected.   This leads to the conclusion that at least some commercial Taq polymerases have 
plasmid contamination.  Usually this is not an issue as the researcher is using primers specific to 
the gene of interest or the MCS of the plasmid.  In both cases these are unique; however, there is 
no reason to believe that many plasmids might not have the same origin of replication.  The 
ultimate question from all of this is where is the contaminating DNA signal coming from?  Is it 
plasmid contamination in the RNA prep or the plasmid in the polymerase prep.  The constant 
presence of this signal makes it difficult to state whether any signal detected during actual RT-
PCR results from RNA or contaminating DNA.  Treating the polymerase itself with DNase 
worked with controls that were spiked with a template.  However this treated polymerase was 
unable to generate a signal when used with the controls in the Ambion RT-PCR kit.   
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 6 Conclusions 
 Overall this appears to have been a successful thesis.  The desired antimicrobial peptide 
was expressed and displayed antimicrobial activity.  Although PG-1 was expressed by the 
bacteria it was in very small quantities.  This could be due to any of the factors outlined above.  
The work done here represents the first successful cloning of the PG-1 peptide in a bacterial 
system and supports the feasibility of producing antimicrobial peptides by cloning.  It also 
further supports the fusion protein approach while highlighting that the choice of fusion partner 
is an important consideration. Future work involving optimization of expression may be able to 
improve the yield of this system to the point where it may be detectable by simple SDS-PAGE 
analysis.  Using a plasmid construct with the PG-1 gene repeated such that each successful 
transcription/translation event results in multiple PG-1 peptides linked together with cleavage 
sites between them may also be a viable option.  As mentioned in the Background, tandem 
repeats were used to good effect in the expression of recombinant buforin II (Lee et al. 1997).   A 
different fusion tag partner may also increase expression.  It seems that the his-tag complex used 
here only did an average job of limiting PG-1’s antimicrobial activity considering the non-
cleaved fusion peptide was active.  The F4 protein mentioned previously may be better suited to 
inclusion body formation and overall stability.  Expression in alternative systems may also be 
explored if a cloning approach is still desired.  A mammalian system would seem most 
favorable.  Due to differences in mammalian membrane structure it is likely that many of the 
toxic effects of PG-1 would not be an issue.  Engineering the protein so that it is exported out of 
the cell after production may also be possible with a mammalian system.  This would greatly 
simply purification.  Given the small size of the protein, synthetic manufacturing can and has 
been used to produce the peptide.  Intrabiotic’s protegrin analogue is synthetically manufactured 
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 and is in Phase III FDA trials as stated above.  The only drawback to this system is the 
production of some environmentally hazardous compounds, particularly triflouroacetic acid.    
 Antimicrobial peptides have great potential in fighting bacterial, viral, and fungal 
infections.  With the number of antibiotic resistant bacterial strains increasing it is getting 
increasingly difficult to treat infections using conventional means.  So far no evidence has been 
seen of bacterial resistance to PG-1.  Hopefully this will remain true for some time as true 
resistance would, in the case of PG-1, require substantial restructuring of the bacterial membrane 
and cell wall.  While difficult, this restructuring is possible as there are many strains of bacteria 
that currently can resist antimicrobial peptides by membrane alterations which reduce negative 
electrical charge.  With further research these peptides have the potential to become a significant 
tool in controlling the spread of microbial infections.   
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Appendix A: Laboratory Protocols 
A-1 Agarose Gel Electrophoresis 
 
BAGSHAW LAB PROTOCOLS 
 
AGAROSE GEL ELECTROPHORESIS 
 
Agarose gel electrophoresis is a simple and effective method for separating DNA fragments in 
the range of 0.5-25 kilobase pairs.  DNA is a polyanion because of the phosphate groups, and 
thus will migrate toward the anode in an electric field.  The charge-to-mass ratio is the same for 
all DNA's, so the fragments separate according to size (length) because of the seiving effect of 
the agarose gel:  the smaller the fragment, the faster it migrates.  By including marker DNA 
fragments of known length (e.g. restriction digests of lambda DNA), you can measure the length 
of unknown fragments (see "Recombinant DNA Coloring Book"). 
 
The principal variable in agarose gel electrophoresis is the percentage of agarose (g/100 ml) in 
the gel.  A 1.0% gel is more porous than a 1.5% gel, and all DNA fragments will migrate faster 
in a 1.0% gel than in a 1.5% gel.  The migration rate, and thus the time needed to complete a run, 
can also be changed by changing the voltage, and this has some effect on resolution. 
 
Materials 
 Electrophoresis buffer (TBE) 
 Ethidium bromide solution 
 Electrophoresis-grade agarose 
 DNA molecular weight markers 
 55°C water bath or incubator 
 Horizontal gel electrophoresis apparatus 
 Gel casting tray and comb (slot former) 
 DC power supply 
 Two-cycle semi-log graph paper 
 
1.  Weigh out the agarose and measure (graduated cylinder) the TBE buffer.  How much of each 
you will need depends on which electrophoresis apparatus you are using and what percent gel 
you want to make.  For example, to make a 1% gel you would use 0.5 g of agarose in 50 ml of 
buffer, or 2 g of agarose in 200 ml of buffer.  Place the buffer in a flask or screw-cap bottle, add 
the agarose and swirl.  Put the flask (with a foil cover or slip-on cap) or the lightly (not tightly) 
capped bottle in a bioling water bath.  A Rival Hot-Pot is very convenient.  Check the flaskor 
bottle and swirl it occassionally.  When the agarose is properly melted the solution will be crystal 
clear. 
 
An alternative way to melt the agarose is to "nuke" it in a microwave oven.  Remember: do not 
put aluminum foil in a microwave.  Use a plastic cap on a flask or a screw cap bottle.  Start with 
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 one minute on high power, then check the bottle.  If the agarose is not yet melted, "nuke" it some 
more in 20 second increments.  Don't let the solution boil over. 
 
After the agarose solution has been prepared, it must be cooled to about 55o before it can be 
poured.  The most convenient way to do this is to leave it in a water bath or incubator for a few 
hours, even overnight.  If you're in a hurry, let the flask or bottle stand on the bench until it is  
 
cool enough.  Put a thermometer in the solution, and swirl it occassionally.  If you're really in a 
hurry, run cold water on the outside of the flask or bottle while you swirl it. 
 
 
2. While the agarose solution is cooling, prepare the gel tray.  Place the casting tray, with the gel 
tray inside it, on a level surface (one of the black plastic platforms with the four threaded legs 
and built-in levelling bubble is best) and position the comb (slot former) so that the teeth are 
about 1mm above the bottom of the gel tray and 0.5 cm from one end.  When the agarose 
solution has cooled, pour it into the gel tray.  Allow at least one half hour for the gel to set and 
cool.  As it sets, the gel will become translucent. 
 
3. Carefully pull the comb straight up out of the gel.  Remember that the partitions between wells 
must not be broken.  Now remove the gel tray from the casting tray.  This can be difficult, 
especially with the small gels, because the gel that formed outside the gel tray tends to form a 
seal.  It often helps to take a spatula and run it between the outside edge of the gel tray and the 
casting tray. 
 
4.  Fill the electrophoresis apparatus until the buffer covers the support where the gel tray will 
rest.  Lower the gel tray into the apparatus, leaving no bubbles under it.  If necessary, add more 
buffer so that the gel is covered by about 1 cm. 
 
5.  Carefully pipet your samples into the wells of the gel, layering them smoothly under the 
buffer.  Be very careful not to puncture the bottom of the well or damage the partitions between 
wells.  It is not necessary to put the pipet tip far down into the well.  Put the lid on the apparatus, 
plug it into the DC power supply, and run it at 12 volts overnight.  Be sure the lid is oriented so 
that the DNA migrates toward the anode (red).  Remember: RUN TO THE RED. 
 
6.  Here's an alternative way to load the gel and start the run.  This is especially useful when you 
need to get the maximum amount of sample into the well, and also when you are running 
precious samples that you can not afford to lose.  Put enough buffer in the electrophoresis 
apparatus so that the buffer comes up to the ends of the gel but does not cover the gel.  The 
wells at this point should be completely empty.  Load your DNA samples into the wells, and if 
there are any empty wells, fill them with buffer.  Turn on the power supply and let the gel run for 
about 1/2 hour.  At this point the DNA has migrated into the gel, if only a fraction of a 
centimeter.  Now cover the gel with buffer and resume the run. 
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GEL STAINING AND ANALYSIS 
 
The method of staining most commonly used for DNA uses ethidium bromide (EB), a dye that 
intercalates between the planar base pairs of double-stranded DNA.  EB fluoresces when 
irradiated with ultraviolet light; The fluorescence is weak for free EB but very intense when the 
dye is bound to DNA.  CAUTION:  EB is one of the few toxic substances you will use in this 
lab.  It is a known mutagen and thus a potential carcinogen.  Always wear gloves when carrying 
gels or solutions containing EB, and dispose of solutions only in the designated waste container. 
 
1.  After unplugging the DC power supply, carefully lift the gel, still in its tray, out of the 
electrophoresis apparatus and place it in a plastic box.  Cover the gel with 0.5 mg/ml EB and 
stain the gel for at least 30 minutes with occasional gentle shaking.  It is even better to leave the 
gel in the stain solution while you're doing other things, then photograph it when convenient. 
 
2.  Pour off the solution into the designated waste container and cover the gel with distilled 
water.  You can photograph your gel now or later.  Note:  This destaining step is not strictly 
necessary, but it will reduce background and enhance contrast.  This can be important when you 
are running genomic DNA digests, or when you are trying to see faint bands. 
 
3.  Carefully place your gel on the UV light box.  Place a clear plastic ruler along one side of the 
gel so that the edge of the ruler lies on top of or beside the gel and the zero mark is at the edge of 
the well. 
 
4.  Photograph the gel and develop the film.  Using the image of the ruler on the photo, measure 
the distance migrated (in cm) for each DNA band. 
 
5.  From the data on restriction sites in your marker DNA,  determine the exact length of each 
fragment in your marker samples.  Alternatively, if you are using a commercially prepared 
marker, the product data sheet should give you the fragment lengths.  Using semi-log graph 
paper, plot fragment length on the log scale vs. migration distance on the linear scale and draw 
the best-fit curve.  All the marker data (e.g. l/Eco RI and l/Hind III should fit a single standard 
curve.  If they don't, you did something wrong. 
 
6.  From the migration distance of bands in lanes containing fragments of unknown size, 
determine the length of each fragment. 
 
10 X TBE buffer, 1 l 
 Tris   107.8 g 
 Boric acid   55.0 g 
 EDTA      7.4 g 
 Dissolve and adjust to 1 l, no need to check pH 
 
Ethidium bromide stain solution 
 
 Fill 2 l foil-wrapped bottle with water. 
 Add 100ml ethidium bromide, 5 mg/ml 
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 A-2 Cycle Sequencing with ABI Ready Reaction 
 BAGSHAW LAB PROTOCOLS 
 
 CYCLE SEQUENCING WITH ABI READY REACTION 
 
Plasmid DNA Purification.  The quality of the plasmid DNA template is critical to the success of 
DNA sequencing.  For automated sequencing on the ABI 310 Genetic Analyzer using the ABI 
Ready Reaction chemistry, the DNA must be in water, not in TE bufer, and must be at a 
concentration of at least 0.1 µg/µl.  We prefer the Qiaprep plasmid mini-prep kit from Qiagen.  
Grow a 5 mL culture of cells, spin down the whole lot, and isolate plasmid DNA according to the 
kit protocol.  Be sure to elute the DNA in water.  Run a 2 µl sample overnight on a gel, 
preferably with a standard of known concentration, to estimate the DNA concentration.  If there 
is any evidence of host cell DNA or RNA contamination, reject the prep and do over. 
 
 
Cycle Sequencing 
 
1. For each reaction, combine the following in a 0.5 mL PCR tube: 
 
                  8 µl      ABI Ready Reaction mix 
                           4 µl      primer, 1.0 pmol/ µl 
                  1-8 µl   plasmid DNA 
                  sterile reagent grade water to 20 µl 
 
2. Cover each reaction mix with a drop of mineral oil and spin briefly to collect everything at 
the bottom of the tube. 
 
3. Cycle program: 96o, 15 seconds; 50o, 15 seconds; 60o, 4 minutes; 25 cycles.  On our MJ 
Research cycler this program is named ABI. 
 
 
Product Purification 
 
1. Carefully transfer the reaction mix to one of the ABI sample tubes.  These look like PCR 
tubes but have no lids.  It is important not to transfer any mineral oil.  With the plunger of the 
micropipettor depressed, push the tip of the tip to the bottom of the tube, and release the 
plunger slowly.  After withdrawing the tip from the reaciton tue, wipe the outside with a 
Kimwipe to remove mineral oil, then transfer the reaction. 
 
2. To each reaction mix add 75 µl of 70% ethanol containing 0.5 mM MgCl2.  Mix thoroughly 
and let stand 15 minutes at room temperature. 
 
3.  Centrifuge tubes 15-20 minutes in a microcentrifuge.  Mark and orient the tubes so that you 
will know where the pellet should be.  Carefully pipet off the supernatant without disturbing 
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 the invisible pellet.  Immediately wikc off the last tiny drop of liquid with a Kimwipe tip (one 
corner of a Kimwipe twirled into a fine tip).  Proceed to the next sample. 
 
4. Dry all the samples in the 55o incubator for at least 15 minutes.  If you are not going to run 
the samples immediately, stop here, place a rubber septum in each tube, and store the 
samples in the refrigerator. 
 
 
Preparing samples for the run 
 
1. To each tube add 20 µl of Template Suppression Reagent.  Replace (or place) the rubber 
septum and vortex each sample vigorously to dissolve the extension products. 
 
2. Denature the reaction products by placing the tubes in a boiling water bath, or in the MJR 
cycler set on “Denature,” for three minutes.  Chill in an ice water bath. 
 
3. Spin the samples briefly to collect everything at the bottom of the tube.  The samples are now 
ready to be loaded into the instrument. 
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 A-3 Ligation 
Ligation Protocol 
Adapted from Laboratory DNA Science (Bloom et al. 1996) 
 
 
1. Ligation reaction mix:   
 
 3ul digested pBluescript,  
 3ul elongation mixture,  
 2ul 10X reaction buffer,  
 11ul H2O  
 1ul T4 ligase.   
 
2. Combined all of these ingredients into a single Eppendorf tube and mixed.  The mixture was 
then incubated at room temperature for three hours.  
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 A-4 Plasmid Mini-Preps 
 
BAGSHAW LAB PROTOCOLS 
 
 PLASMID MINI-PREPS 
 
 This protocol is useful when you need a small amount of a large number of different 
plasmids, for example to verify the sizes in a cloning or re-construction experiment.  It is exactly 
like the large-scale prep but on a small scale.  You can easily do two or three dozen plasmid 
mini-preps in a day. 
 
Day before:  For each plasmid mini-prep, inoculate 5 ml of L + Amp medium with a single 
colony from a recent plate.  Shake overnight at 37o; the rotating platform in the incubator cabinet 
is convenient for this.  (Note: all plasmids constructed with pBluescript, and most of the others 
we use, have the AmpR marker.  A few have the TetR instead; in that case substitute L + Tet.) 
 
Prep day: 
 
1.  For each mini-prep, pellet the cells from the overnight culture by centrifugation.  Ten minutes 
in the bench-top centrifuge, a.k.a.”mushroom”, at setting 5 will do nicely. Pour off the 
supernatant into the liquid biohazard waste container, drain the tube thoroughly and wipe the 
remaining supernatant from the inside of the tube with a Kimwipe.  Remember to dispose of the 
Kimwipe in the solid biohazard waste container 
 
2.  Resuspend the cells in each centrifuge tube in 0.2 ml of 25 mM Tris/ 50 mM EDTA, pH 8.0.  
Vortexing is OK at this step.  Transfer each suspension to a 1.5 ml microcentrifuge tube. 
 
3.  Add 0.4 ml of freshly prepared 0.2 M NaOH/1% SDS and mix by gently rocking the tubes.  
Do not vortex!  The extract at this step becomes very viscous, then clears slightly.  Set on ice for 
10 minutes. 
 
4.  Add 0.3 ml of cold 5 M potassium acetate solution (3 M KOAc and 2 M acetic acid, pH 4.8), 
mix thoroughly but gently, and leave on ice for 5 minutes. 
 
5.  Centrifuge for 15 minutes, then transfer the supernatant to a clean 1.5 ml microcentrifuge 
tube.  Be very careful not to transfer any of the precipitate. 
 
6.  Add 0.5 ml of isopropanol, mix thoroughly and let stand at room temperature for 2 minutes or 
longer. (Note: This is the first point at which, if necessary or convenient, you can interrupt the 
protocol and resume the next day.  Leave the plasmid prep in isopropanol at room temperature, 
then resume the protocol with the centrifugation step.) 
 
7.  Centrifuge for 10 minutes, then carefully remove and discard the supernatant.  Dissolve the 
precipitate in 50 µl of TE buffer.  
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8.  Add 25 µl of 7.5 M ammonium acetate and leave on ice for 20 minutes or more.  A 
convenient alternative is to add the ammonium acetate and leave the tubes on ice or in the 
refrigerator while you do something else, or until after lunch, or the next day.  Whatever. 
 
9.  Centrifuge for 10 minutes and transfer the supernatant to a clean microcentrifuge tube.  Add 
200 ml of ethanol and let stand at room temperature 2 minutes or longer. 
 
10.  Centrifuge for 10 minutes, then carefully remove and discard the supernatant.  Air dry the 
pellet and dissolve it in 50 µl of TE buffer containing 10 µg/ml RNase A.  Store in the 
refrigerator.  Run 5 µl on a 1% agarose gel to check the quantity and quality of the plasmid 
DNA. 
 
1.0 M Tris, pH 8.0 
 Dissolve 12.1 g Tris base in distilled water.  Adjust pH to 8.0 with concentrated  HCl, 
and volume to 100 ml with distilled water. 
 
0.5 M EDTA, pH 8.0 
           Dissolve 18.6 g disodium EDTA dihydrate and 2.6 g NaOH in distilled water, and  adjust 
volume to 100 ml. 
 
25 mM Tris/50 mM EDTA, pH 8.0 
 1.0 M Tris, pH 8.0  2.5 ml 
 0.5 M EDTA, pH 8.0  10 ml 
 Water to 100 ml, autoclave 
 
0.2 M Na OH, 1% SDS 
 Sodium dodecyl sulfate (SDS), 2 g, water to 100 ml 
 NaOH, 1.6 g, water to 100 ml 
 Mix equal volumes before use. 
 
TE buffer 
 1 M Tris, pH 8.0  1.0 ml 
 0.5 M EDTA, pH 8.0  0.2 ml 
 Water to 100 ml, autoclave 
 
5 M potassium acetate 
 Potassium acetate  29.44 g 
 Glacial acetic acid  11.5 ml 
 Water to 100 ml 
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 A-5 Restriction Enzyme Digestion 
BAGSHAW LAB PROTOCOLS 
 
 RESTRICTION ENZYME DIGESTION 
 
The protocol described here is appropriate for digesting plasmid or lambda DNA for mapping, 
subcloning, making probes, etc.  We have a different protocol for digestions of genomic DNA. 
 
Cleavage of DNA into a set of discrete fragments by digestion with a restriction endonuclease is 
the most fundamental operation in recombinant DNA work.  The reaction is accomplished 
simply by incubating the DNA and enzyme together in a small volume under appropriate buffer 
conditions.  Like all enzymes, each restriction endonuclease requires a specific pH, ionic 
concentration and temperature for optimal activity.  However, most of these enzymes will work 
well under one of a small set of conditions.  Most suppliers of restriction enzymes also provide a 
"10X buffer", which contains all the necessary buffers and salts at pricisely 10 times the right 
concentration for the enzyme reaction.  Therefore, in order to make a reaction mix of any desired 
volume, you will use 1/10 that volume of 10X buffer.  It is absolutely essential that you use the 
right buffer for each enzyme, so when you are using several different enzymes you must pay 
attention to which buffer you use in each reaction.  The restriction enzymes we use most are 
from New England Biolabs, and the accompanying 10X buffers have names like "NEBuffer 
EcoRI" or "NEBuffer 2".  We store the 10X buffer together with the enzyme, so you should 
always be able to find it. 
 
Restriction enzymes will lose activity if they are mistreated, particularly if they are not kept cold.  
NEVER let restriction enzymes sit on the bench top while you set up the digestion reaction or do 
other things.  The restriction enzyme is always the last component added to the reaction mix, so 
leave it in the freezer until everything else is ready.  Take the enzyme from the freezer and 
immediately place it on ice.  You don't need a big ice bucket for this; a small plastic container or 
styrofoam cup filled with crushed ice will suffice.  After you have added the enzyme to your 
digestion reactions, immediately return the enzyme to the freezer.   
 
The following is a generic protocol for a restriction enzyme digestion in a volume of 20 ml.  This 
volume is appropriate when the entire sample will be used for a single agarose gel run.  
Sometimes you will need to prepare larger volumes so you have enough for two or more gel 
runs, subsequent digestion with a second enzyme, ligation, etc., and to do that you would keep 
the proportions of all components constant.  For example, if you wanted to make a reaction mix 
of 100 ml, you would use 10 ml of 10X buffer.  However, you might not use 5 ml of enzyme.  
Most enzymes are at a concentration of 10 units/ml, and one unit will digest one mg of DNA in 
one hour.  Using 50 units is probably a waste, and some of these enzymes are expensive. 
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 Materials 
DNA to be digested 
10X restriction endonuclease buffers 
Restriction endonucleases  
Stop mix 
 
1. Pipet the following into a clean 0.5 ml microcentrifuge tube: 
 
 X ml DNA (0.1 to 1 mg DNA in H2O or TE buffer) 
     2 ml 10X restriction buffer  
     17 - X ml H2O 
 
Note:  The value of x in this recipe depends on the concentration of the DNA.  If the DNA is 
very concentrated you might use only 1 ml and add 16 ml of H2O.  If the DNA is dilute, you 
might need to use 17 ml of DNA and no water at all.   
 
 
2.  Add 1 ml of restriction endonuclease (1 to 5 units/mg DNA), mix the sample gently but 
thoroughly, and incubate the reaction mixture 1 hr. or more at the recommended temperature (in 
general, 37°C).  It is often convenient to incubate for a longer time, e.g. set up the reactions in 
the morning, incubate all day and then run an agarose gel overnight. The volume of restriction 
endonuclease added should be no more than 1/10 the volume of the final reaction mixture, 
because glycerol in the enzyme storage buffer may interfere with the reaction. 
  
The restriction enzymes are in a solution containing 50% glycerol, which is thus very dense and 
viscous.  It is absolutely critical that the enzyme is thoroughly mixed into the reaction mixture.  
If mixing is incomplete, your restriction digestion will be incomplete, or won't work at all.  This 
is the most common cause of failure among novice gene jockeys.  Hold the tube up to a light and 
gently flick the tip with your finger.  Even though the contents are colorless, you will see a swirl 
of refracted light, called a Schlieren pattern, that results from the mixing of solutions that have 
different refractive indices.  When the Schlieren pattern disappears, your sample is mixed. 
 
3.  After incubation, stop the reaction by adding 5ml of stop mix.  This contains the following:  
ficoll, a sucrose polymer for density; EDTA to chelate Mg++; sodium dodecyl sulfate (SDS) to 
denature proteins; bromphenol blue, a tracking dye.  Mix thoroughly and incubate 5 min. at 65°.  
The sample is now ready for electrophoresis.  Note:  After a restriction digestion and before you 
add stop mix (which contains SDS, a protein denaturant) think about what you're going to do 
with the digest.  If the entire sample is going to be run on a gel, either now or later, go ahead and 
add the stop mix.  But if you are going to use the DNA for ligation, further digestion or other 
enzymatic reaction, do not add stop mix to the whole reaction. 
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 A-6 Transformation  
TRANSFORMATION PROTOCOL 
FOR TOP10F’ E. coli 
Adapted from Zero Blunt® TOPO® PCR Cloning Kit  
for Sequencing Manual 
(Invitrogen Carlsbad, CA) 
 
1. Add 2 µL of the cloning reaction into a vial of TOP10F’ One Shot® Chemically 
Competent E. coli and mix gently.  Do not mix by pipetting up and down. 
 
2. Incubate on ice for 5 to 30 minutes. 
 
3. Heat-shock the cells for 30 seconds at 42o C without shaking. 
 
4. Immediately transfer the tubes to ice. 
 
5. Add 250 µL of room temperature SOC medium. 
 
6. Cap the tube tightly and shake the tube horizontally (200 rpm) at 37 o C for one hour. 
 
7. Spread 10-50 µL from each transformation on a prewarmed selective plate and incubate 
overnight at 37 o C.   
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